[
  {
    "ts": "2026-01-28T00:21:49+00:00",
    "headline": "Assessing Boston Scientific (BSX) Valuation After The Penumbra Deal And Recent Share Moves",
    "summary": "Boston Scientific stock snapshot after recent moves Boston Scientific (BSX) has seen mixed returns recently, with the share price close to US$93.61 after a modest gain over the past week but declines over the past month and past 3 months. See our latest analysis for Boston Scientific. That recent short term share price weakness, with a 30 day share price return of a 2.55% decline and a 90 day share price return of a 6.67% decline, sits against a three year total shareholder return of 102.40%...",
    "url": "https://finance.yahoo.com/news/assessing-boston-scientific-bsx-valuation-002149229.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "d6bfcb1f-216c-3ba0-a1d9-6978a4d6b08b",
      "content": {
        "id": "d6bfcb1f-216c-3ba0-a1d9-6978a4d6b08b",
        "contentType": "STORY",
        "title": "Assessing Boston Scientific (BSX) Valuation After The Penumbra Deal And Recent Share Moves",
        "description": "",
        "summary": "Boston Scientific stock snapshot after recent moves Boston Scientific (BSX) has seen mixed returns recently, with the share price close to US$93.61 after a modest gain over the past week but declines over the past month and past 3 months. See our latest analysis for Boston Scientific. That recent short term share price weakness, with a 30 day share price return of a 2.55% decline and a 90 day share price return of a 6.67% decline, sits against a three year total shareholder return of 102.40%...",
        "pubDate": "2026-01-28T00:21:49Z",
        "displayTime": "2026-01-28T00:21:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sFax.1EIpS7VVYvaDN0jRw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OB69YGFZw788CGHTsahrkQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-boston-scientific-bsx-valuation-002149229.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-boston-scientific-bsx-valuation-002149229.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            },
            {
              "symbol": "PEN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T14:04:46+00:00",
    "headline": "Boston Scientific Corporation (BSX): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Boston Scientific Corporation on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on BSX. Boston Scientific Corporation’s share was trading at $93.61 as of January 27th. BSX’s trailing and forward P/E were 50.06 and 26.95 respectively according to Yahoo Finance. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. BSX presents a tac",
    "url": "https://finance.yahoo.com/news/boston-scientific-corporation-bsx-bull-140446278.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "1ed98d42-be7f-347e-88f8-9fed5fc84a96",
      "content": {
        "id": "1ed98d42-be7f-347e-88f8-9fed5fc84a96",
        "contentType": "STORY",
        "title": "Boston Scientific Corporation (BSX): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Boston Scientific Corporation on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on BSX. Boston Scientific Corporation’s share was trading at $93.61 as of January 27th. BSX’s trailing and forward P/E were 50.06 and 26.95 respectively according to Yahoo Finance. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. BSX presents a tac",
        "pubDate": "2026-01-28T14:04:46Z",
        "displayTime": "2026-01-28T14:04:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/d2c13a2e52f04c053339c33cfeefc5b3",
          "originalWidth": 1410,
          "originalHeight": 1920,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CL6QBVVKqNjFiA0HBvRbrA--~B/aD0xOTIwO3c9MTQxMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/d2c13a2e52f04c053339c33cfeefc5b3.cf.webp",
              "width": 1410,
              "height": 1920,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ainVD02_4fJlkltE7krYjQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d2c13a2e52f04c053339c33cfeefc5b3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/boston-scientific-corporation-bsx-bull-140446278.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/boston-scientific-corporation-bsx-bull-140446278.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            },
            {
              "symbol": "PEN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T13:24:00+00:00",
    "headline": "Reasons to Retain Baxter International Stock in Your Portfolio Now",
    "summary": "BAX is reshaping its portfolio following the divestiture of its Kidney Care business, focusing on surgical strength, deleveraging and tighter execution to rebuild momentum.",
    "url": "https://finance.yahoo.com/news/reasons-retain-baxter-international-stock-132400760.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "48a55193-98b7-3b16-b41c-c49e8859d6f1",
      "content": {
        "id": "48a55193-98b7-3b16-b41c-c49e8859d6f1",
        "contentType": "STORY",
        "title": "Reasons to Retain Baxter International Stock in Your Portfolio Now",
        "description": "",
        "summary": "BAX is reshaping its portfolio following the divestiture of its Kidney Care business, focusing on surgical strength, deleveraging and tighter execution to rebuild momentum.",
        "pubDate": "2026-01-28T13:24:00Z",
        "displayTime": "2026-01-28T13:24:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/28fc1568786cf7bd1a1b4ba4d8d32823",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fQd2jtWHFbmxXJ2c6MMw9w--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/28fc1568786cf7bd1a1b4ba4d8d32823.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kE5Z17rnuLCB.q0339y1xQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/28fc1568786cf7bd1a1b4ba4d8d32823.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/reasons-retain-baxter-international-stock-132400760.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/reasons-retain-baxter-international-stock-132400760.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAX"
            },
            {
              "symbol": "RMD"
            },
            {
              "symbol": "RSMDF"
            },
            {
              "symbol": "BSX"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T12:27:00+00:00",
    "headline": "Will Robust MedSurg Performance Fuel Boston Scientific's Q4 Earnings?",
    "summary": "BSX heads into Q4 earnings with strong MedSurg momentum and Cardiovascular growth, as revenue and EPS estimates point to double-digit gains.",
    "url": "https://finance.yahoo.com/news/robust-medsurg-performance-fuel-boston-122700137.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "60e7a8a4-753a-37af-88d9-3a470991c5e9",
      "content": {
        "id": "60e7a8a4-753a-37af-88d9-3a470991c5e9",
        "contentType": "STORY",
        "title": "Will Robust MedSurg Performance Fuel Boston Scientific's Q4 Earnings?",
        "description": "",
        "summary": "BSX heads into Q4 earnings with strong MedSurg momentum and Cardiovascular growth, as revenue and EPS estimates point to double-digit gains.",
        "pubDate": "2026-01-28T12:27:00Z",
        "displayTime": "2026-01-28T12:27:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/863d153925c0cc5950906ad3869a2441",
          "originalWidth": 620,
          "originalHeight": 526,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QnonRcRxvBcES83yw1mIMQ--~B/aD01MjY7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/863d153925c0cc5950906ad3869a2441.cf.webp",
              "width": 620,
              "height": 526,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hpkSOn9LSx9RBAhEDv3QzQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/863d153925c0cc5950906ad3869a2441.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/robust-medsurg-performance-fuel-boston-122700137.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/robust-medsurg-performance-fuel-boston-122700137.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            },
            {
              "symbol": "CAH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]